The Supralimus®sirolimus-eluting stent
- 1 May 2013
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Medical Devices
- Vol. 10 (3), 295-300
- https://doi.org/10.1586/erd.12.91
Abstract
The use of biodegradable polymeric coatings has emerged as a potential bioengineering target to improve the vascular compatibility of coronary drug-eluting stents (DESs). This review summarizes the main features and scientific facts about the Supralimus sirolimus-eluting stent (Sahajanand Medical Technologies Ltd, Surat, India), which is a biodegradable polymer-based, sirolimus-eluting metallic stent that was recently introduced for routine use in Europe. The novel stent is built on a stainless steel platform, coated with a blend of biodegradable polymers (poly-l-lactide, poly-dl-lactide-co-glycolide and polyvinyl pyrrolidone; coating thickness is 4-5 µm). The active agent is the antiproliferative sirolimus in a dose load of 1.4 µg/mm(2), which is released within 48 days. The Supralimus stent was initially evaluated in the single-arm SERIES-I study, which showed binary angiographic restenosis rates of 0% (in-stent) and 1.7% (in-segment) and an in-stent late lumen loss of 0.09 ± 0.28 mm. The multicenter randomized PAINT trial compared two DESs with identical metallic platforms and biodegradable polymer carriers, but different agents (Infinnium [Sahajanand Medical Technologies Pvt Ltd] paclitaxel-eluting stent or Supralimus sirolimus-eluting stent) against bare stents. After 3 years, the pooled DES population had similar rates of cardiac death or myocardial infarction (9 vs 7.1%; p = 0.6), but a lower risk of repeat interventions (10 vs 29.9%; p < 0.01) than controls with bare stents. The incidence of definite or probable stent thrombosis in the pooled DES group was 2.3% (1st year: 1.8%; 2nd year: 0.4% and 3rd year: 0%). These results demonstrate that the novel Supralimus stents are effective in reducing reintervention, while potentially improving the safety profile by decreasing the risk of late-term thrombosis, even though further studies would be necessary to confirm these findings.Keywords
This publication has 19 references indexed in Scilit:
- A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patientsEuroIntervention, 2011
- Fundamento e desenho do teste randomizado PAINTArquivos Brasileiros de Cardiologia, 2009
- Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-Year results of the PAINT trialCatheterization and Cardiovascular Interventions, 2009
- Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancerEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Preparation and cell affinity of microtubular orientation-structured PLGA(70/30) blood vessel scaffoldBiomaterials, 2008
- Late Stent ThrombosisCirculation, 2007
- Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH RegistryEuropean Heart Journal, 2006
- Surface modification of interconnected porous scaffoldsJournal of Biomedical Materials Research Part A, 2005
- Comparison of Late Luminal Loss Response Pattern After Sirolimus-Eluting Stent Implantation or Conventional StentingCirculation, 2004
- Atherosclerotic Vascular Disease ConferenceCirculation, 2004